Fortress Biotech Inc (NASDAQ:FBIO) has a beta value of 1.69 and has seen 1.15 million shares traded in the last trading session. The company, currently valued at $48.64M, closed the last trade at $1.76 per share which meant it gained $0.03 on the day or 2.02% during that session. The FBIO stock price is -151.7% off its 52-week high price of $4.43 and 29.55% above the 52-week low of $1.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.73 million shares traded. The 3-month trading volume is 551.83K shares.
The consensus among analysts is that Fortress Biotech Inc (FBIO) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 1 have rated the stock as Underweight. The expected earnings per share for the stock is -0.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fortress Biotech Inc (NASDAQ:FBIO) trade information
Sporting 2.02% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the FBIO stock price touched $1.76 or saw a rise of 14.98%. Year-to-date, Fortress Biotech Inc shares have moved -41.36%, while the 5-day performance has seen it change -12.62%. Over the past 30 days, the shares of Fortress Biotech Inc (NASDAQ:FBIO) have changed 11.01%. Short interest in the company has seen 2.57 million shares shorted with days to cover at 2.99.
Fortress Biotech Inc (FBIO) estimates and forecasts
Figures show that Fortress Biotech Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -0.84% over the past 6 months, with this year growth rate of 68.71%, compared to 17.30% for the industry. Revenue growth from the last financial year stood is estimated to be -3.50%.
2 analysts offering their estimates for the company have set an average revenue estimate of 32.22M for the current quarter. 2 have an estimated revenue figure of 21.42M for the next ending quarter. Year-ago sales stood 34.75M and 19.95M respectively for this quarter and the next, and analysts expect sales will shrink by -7.30% for the current quarter and -3.50% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 22.28% over the past 5 years. Earnings growth for 2024 is a modest 63.40% while over the next 5 years, the company’s earnings are expected to increase by 25.50%.
FBIO Dividends
Fortress Biotech Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Fortress Biotech Inc (NASDAQ:FBIO)’s Major holders
Insiders own 21.21% of the company shares, while shares held by institutions stand at 14.68% with a share float percentage of 18.63%. Investors are also buoyed by the number of investors in a company, with Fortress Biotech Inc having a total of 54.0 institutions that hold shares in the company.
